Please login to the form below

MK-3475

This page shows the latest MK-3475 news and features for those working in and with pharma, biotech and healthcare.

GSK wins approval for skin cancer drug Mekinist in EU

be taken up by immune checkpoint inhibitors - BMS' nivolumab and Merck &Co's pembrolizumab (MK-3475) - which are currently in late-stage testing.

Latest news

Merck could win anti-PD1 therapy race in Europe

Pembrolizumab (formerly lambrolizumab; MK-3475) is one of the highlights of Merck's R&D pipeline and is being evaluated across more than 30 types of cancer, with peak sales estimated
ASCO: Merck’s anti-PD1 impresses in skin and lung cancer

Promising MK-3475 immunotherapy to be known as pembrolizumab. New data on Merck &Co's recently-filed anti-PD1 drug pembrolizumab (MK-3475) suggest the drug could be a 'paradigm shift'
AZ starts pivotal trials of lung cancer immunotherapy

Meanwhile, Merck &Co's MK-3475 - filed for melanoma earlier this year - and Bristol-Myers Squibb's nivolumab for NSCLC are targeting a related receptor called PD1.
FDA grants priority review to Merck’s cancer antibody

The latest news from the FDA continues to back this belief and puts MK-3475 on course to be the first anti-PD-1 antibody approved in the US. . ... Merck has also signed agreements with rivals Pfizer, Amgen and Incyte to test MK-3475 in combination with
Novartis enters PD-1 race via CoStim acquisition

Of these Merck appears to be in the lead, as it has filed a rolling marketing submission for its MK-3475. ... therapies seems backed up by Merck's recent announcement of a series of collaborations on MK-3475 with other drugmakers.

More from news
Approximately 7 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Interview: Bruno Strigini, MSD

Here among the products he points to are the company's anti-PD-1 immunotherapy MK-3475, for which a rolling approval was filed earlier this year as a second-line
Pharma deals during February 2014

Merck &Co also signed three separate agreements with Amgen, Incyte and Pfizer to investigate combination regimes with its experimental anti-PD-1 immunotherapy, MK-3475 (see Box 1). MK-3475 was

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Bruno Strigini leaves Merck & Co for Novartis

Leading the field though is Strigini's former company Merck &Co, which has already filed MK-3475 in the US to treat advanced melanoma.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director, Medical Education: Salary TBC

Senior Medical Writer – Leading Medical Communications Agency – ...: Highly Competitive Remuneration Package

Graduate / Entry Level Opportunities – Medical Communications – ...: Highly Competitive Remuneration Package

Scientific Director - Medical Communications Agency - New York: Excellent Remuneration Package

Senior Medical Writer– Medical Education – Oxford - London: Excellent Remuneration Package

Experienced / Senior Medical Writer - MedComms - Cardiff - Wales: Excellent Salary and Benefits on offer

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Senior / Principal Medical Writer – Medical Education - UK &...: Excellent Salary and Benefits on offer

Senior Medical Writer: Salary TBC

Scientific Director - Medical Education - Cheshire & London ...: Excellent Remuneration Package

Associate Medical Writer / Entry Level Medical Writer - Medical ...: DOE

Account Director – Cheshire based Medical Communications Agency...: D.O.E

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Cello Health

Cello Health are expert navigators, helping healthcare clients uncover hidden insights, explore scientific options and make difficult strategic choices...

Latest intelligence

The 2019 CPhI Pharma Index Report: Examining this year’s industry performance...
Five key trends in precision and personalised healthcare: Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications: Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...